Abstract:The RAS–RAF–MEK–ERK pathway is the most well-studied of the MAPK cascades and is critical for cell proliferation, differentiation, and survival. Abnormalities in regulation resulting from mutations in components of this pathway, particularly in upstream proteins, RAS and RAF, are responsible for a significant fraction of human cancers and nearly all cutaneous melanomas. Activation of receptor tyrosine kinases by growth factors and various extracellular signals leads to the sequential activation of RAS, RAF, MEK, and finally ERK, which activates numerous transcription factors and facilitates oncogenesis in the case of aberrant pathway activation. While extensive studies have worked to elucidate the activation mechanisms and structural components of upstream MAPK components, comparatively less attention has been directed toward the kinases, MEK and ERK, due to the infrequency of oncogenic-activating mutations in these kinases. However, acquired drug resistance has become a major issue in the treatment of RAS- and RAF-mutated cancers. Targeting the terminal kinases in the MAPK cascade has shown promise for overcoming many of these resistance mechanisms and improving treatment options for patients with MAPK-aberrant cancers. Here, we will describe the role of MEK and ERK in MAPK signaling and summarize the current understanding of their interaction and activation mechanisms. We will also discuss existing approaches for targeting MEK and ERK, and the benefits of alternative strategies. Areas requiring further exploration will be highlighted to guide future research endeavors and aid in the development of alternative therapeutic strategies to combat surmounting drug resistance in treating MAPK-mediated cancers. Visual Overview: http://mcr.aacrjournals.org/content/molcanres/19/3/361/F1.large.jpg .

Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

The Overview of Mitogen-activated Extracellular Signal-Regulated Kinase (Mek)-Based Dual Inhibitor in the Treatment of Cancers.

Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors

MEK inhibitor resistance mechanisms and recent developments in combination trials

Developments in Mitogen-Induced Extracellular Kinase 1 Inhibitors and Their Use in the Treatment of Disease

Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.

Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader.

Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders

Discovery of Coumarin-Based MEK1/2 PROTAC Effective in Human Cancer Cells.

Current Development Status of MEK Inhibitors

Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: an Update on Pharmacological Small-Molecule Inhibitors.

Abstract 1947: Studies on pMEK inhibitors for the treatment of RAS-mutant cancers as a single agent or combinations

The MEK/ERK Network as a Therapeutic Target in Human Cancer

Allosteric Modulators of MEK1: Drug Design and Discovery

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Allosteric Modulators of MEK1: Drug design and Discovery.

Design, Synthesis, and Biological Evaluation of Proteolysis-Targeting Chimeras as Highly Selective and Efficient Degraders of Extracellular Signal-Regulated Kinase 5

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy